TY - JOUR
T1 - Associations of Oral Contraceptives with Mammographic Breast Density in Premenopausal Women
AU - Yaghjyan, Lusine
AU - Smotherman, Carmen
AU - Heine, John
AU - Colditz, Graham A.
AU - Rosner, Bernard
AU - Tamimi, Rulla M.
N1 - Funding Information:
This work was supported by the NCI at the NIH (CA131332 and CA175080 to R.M. Tamimi, UM1 CA186107 and P01 CA087969 to M.S., U01 CA176726 to W.W, U01 CA200464 to J. Heine), Avon Foundation for Women, Susan G. Komen for the Cure, and Breast Cancer Research Foundation. We would like to thank the participants and staff of the NHS and NHSII for their valuable contributions as well as the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, and WY. The authors assume full responsibility for analyses and interpretation of these data.
Funding Information:
J. Heine reports patents for US 6,310,967 BI, US 7,664,604, US 10,007,982 B2, US 10,134,148 B2, and US 10,846,856 B2 issued. G.A. Colditz reports grants from NIH during the conduct of the study. B. Rosner reports grants from NIH during the conduct of the study. R.M. Tamimi reports grants from NIH/NCI during the conduct of the study. No disclosures were reported by the other authors.
Publisher Copyright:
© 2021 American Association for Cancer Research.
PY - 2022/2
Y1 - 2022/2
N2 - Background: We investigated the associations of oral contraceptives (OC) with percent breast density (PD), absolute dense area (DA), nondense area (NDA), and a novel image intensity variation (V) measure in premenopausal women. Methods: This study included 1,233 controls from a nested case- control study within Nurses' Health Study II cohort. Information on OCs was collected in 1989 and updated biennially. OC use was defined from the questionnaire closest to the mammogram date. PD, DA, and NDA were measured from digitized film mammograms using a computer-assisted thresholding technique; the V measure was obtained with a previously developed algorithm measuring the SD of pixel values in the eroded breast region. Generalized linear regression was used to assess associations between OCs and density measures (square root-transformed PD, DA, and NDA, and -untransformed V). Results: OC use was not associated with PD [current vs. never: β=-0.06; 95% confidence interval (CI),-0.37-0.24; past vs. never: β= 0.10; 95% CI, -0.09-0.29], DA (current vs. never: β=-0.20; 95% CI -0.59-0.18; past vs. never: β= 0.13; 95% CI, -0.12-0.39), and NDA (current vs. never: β=-0.19; 95% CI, -0.56-0.18; past vs. never: β= -0.01; 95% CI, -0.28-0.25). Women with younger age at initiation had significantly greater V-measure (<20 years vs. never: β= 26.88; 95% CI, 3.18-50.58; 20-24 years vs. never: β= 20.23; 95% CI,-4.24-44.71; 25-29 years vs. never: β=2.61; 95% CI -29.00-34.23; ≥30 years vs. never: β=0.28; 95% CI,-34.16-34.72, Ptrend = 0.03). Conclusions: Our findings suggest that an earlier age at first OC use was associated with significantly greater V.
AB - Background: We investigated the associations of oral contraceptives (OC) with percent breast density (PD), absolute dense area (DA), nondense area (NDA), and a novel image intensity variation (V) measure in premenopausal women. Methods: This study included 1,233 controls from a nested case- control study within Nurses' Health Study II cohort. Information on OCs was collected in 1989 and updated biennially. OC use was defined from the questionnaire closest to the mammogram date. PD, DA, and NDA were measured from digitized film mammograms using a computer-assisted thresholding technique; the V measure was obtained with a previously developed algorithm measuring the SD of pixel values in the eroded breast region. Generalized linear regression was used to assess associations between OCs and density measures (square root-transformed PD, DA, and NDA, and -untransformed V). Results: OC use was not associated with PD [current vs. never: β=-0.06; 95% confidence interval (CI),-0.37-0.24; past vs. never: β= 0.10; 95% CI, -0.09-0.29], DA (current vs. never: β=-0.20; 95% CI -0.59-0.18; past vs. never: β= 0.13; 95% CI, -0.12-0.39), and NDA (current vs. never: β=-0.19; 95% CI, -0.56-0.18; past vs. never: β= -0.01; 95% CI, -0.28-0.25). Women with younger age at initiation had significantly greater V-measure (<20 years vs. never: β= 26.88; 95% CI, 3.18-50.58; 20-24 years vs. never: β= 20.23; 95% CI,-4.24-44.71; 25-29 years vs. never: β=2.61; 95% CI -29.00-34.23; ≥30 years vs. never: β=0.28; 95% CI,-34.16-34.72, Ptrend = 0.03). Conclusions: Our findings suggest that an earlier age at first OC use was associated with significantly greater V.
UR - http://www.scopus.com/inward/record.url?scp=85124207392&partnerID=8YFLogxK
U2 - 10.1158/1055-9965.EPI-21-0853
DO - 10.1158/1055-9965.EPI-21-0853
M3 - Article
C2 - 34862209
AN - SCOPUS:85124207392
SN - 1055-9965
VL - 31
SP - 436
EP - 442
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
IS - 2
ER -